CYP2C19 genetic testing is emerging as a practical tool to tailor antiplatelet therapy for people who need blood thinners after a heart attack, stent placement, or other vascular events. Clinicians are starting to use simple genetic results to decide whether the standard drug will work or whether a different medicine is safer and more effective for an individual patient.